Full Coverage
AbbVie's Q1: Positive Surprise (NYSE:ABBV)
By Jonathan Weber
Top news
Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors
By Annika Kim Constantino & Ashley Capoot
AbbVie’s first-quarter results top expectations as arthritis drugs fuel growth
By Eleanor Laise
AbbVie Q1 Preview: Skyrizi and Rinvoq's launches could help Q1 (NYSE:ABBV)
By Nilanjana Basu
All coverage
AbbVie's Skyrizi proves a worthy Humira successor with nearly matching sales ahead of potential UC nod
By Zoey Becker
Drugmaker AbbVie Expects Humira Volume Erosion to Worsen
By Leroy Leo, Christy Santhosh & Devika Syamnath
AbbVie (ABBV) hikes 2024 earnings guidance as Q1 beat estimates, shares up
By Vahid Karaahmetovic
Drugmaker AbbVie expects Humira volume erosion to worsen
By Leroy Leo & Christy Santhosh
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
By Damien Conover
AbbVie tries to reassure investors on Humira biosimilar threat
By Jonathan D. Gardner
Earnings Beat: AbbVie Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Drugmaker AbbVie expects Humira volume erosion to worsen
By Leroy Leo & Christy Santhosh
Earnings call: AbbVie surpasses Q1 expectations, announces CEO transition
By Natashya Angelica